Project Grant 2537536
- The National Science Foundation (NSF) Division of Chemical, Bioengineering, Environmental, and Transport Systems awarded a $450,000 Project Grant to the Texas A&M Engineering Experiment Station (Tees) to develop an injectable, grain-of-rice size glucose biosensor for continuous blood sugar monitoring. The key products or services to be provided under this 3-year grant include: Developing an injectable glucose biosensor comprised of a self-cleaning membrane and a near-infrared fluorescence...
- This Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program totaling $511,798 was awarded to Kilele Health Inc. on June 15, 2022 to develop continuous diagnostic monitoring platforms beyond glucose sensing. Unlike existing enzymatic glucose sensors, the company will utilize electrochemical aptamer sensors that can rapidly measure other molecules in the body with high specificity and sensitivity. The aim is to address limitations that have...
- Federal Project Grant Award Summary Integrated Medical Sensors Inc. received a $569,998 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 1, 2025 through July 31, 2026. The award funds the development and validation of optimized data processing algorithms for real-time glucose monitoring on the company's proprietary multi-sensor...
- Federal Grant Award Summary Glaive Medical Optics Inc. received a $304,998 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) on October 1, 2025, with completion targeted for September 30, 2026. The awardee will develop a novel implantable intraocular lens device incorporating a low-power, rechargeable visible-light phase shifter and optical phased arrays designed to...
- The National Science Foundation awarded Integrated Medical Sensors Inc. a $256,000 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to develop a novel multi-analyte microsensor platform for continuous wireless monitoring applications. The grant aims to create a unique monolithic semiconductor platform capable of wirelessly monitoring multiple biochemical and physiological markers simultaneously in a sub-cubic millimeter footprint. This miniature,...
- Micromedics Inc. received a $304,926 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation (NSF) Directorate for Technology, Innovation, and Partnerships (CFDA 47.084) effective July 1, 2026, through June 30, 2027. The award funds the design and development of the μPancreas, a wearable bioartificial pancreas device engineered to support insulin-producing cells outside the body for diabetes treatment. The device employs microfluidic technology with thin...
- Federal Grant Award Summary Award Details: Deleon Technologies, Inc. received a $305,000 Small Business Innovation Research (SBIR) Phase I project grant from the National Science Foundation's Directorate for Technology, Innovation, and Partnerships (TIP) under CFDA 47.084, awarded July 1, 2026, with completion targeted for June 30, 2027. Products and Services: The company will develop a low-cost, single-use microfluidic chip that performs capillary electrophoresis with laser-induced fluorescence...
- Federal Grant Award Summary Particle4X, Inc. received a $304,972 Phase I Small Business Innovation Research (SBIR) award from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) effective October 1, 2025, through September 30, 2026. The company is developing a compact, real-time inline monitoring sensor system for injectable drug manufacturing that integrates digital inline holography (DIH) and deep learning algorithms to simultaneously...
- The National Science Foundation (NSF) awarded a three-year, $449,999 Project Grant under their Engineering program (CFDA 47.041) to the University of Cincinnati to develop an implantable biosensor platform that can continuously monitor various biomarkers in the body for over a year. The project aims to create a new class of long-lasting aptamer-based sensors protected by robust porous oxide coatings, which would enable the first practical implantable monitoring system for managing chronic...
- Federal Grant Award Summary In Vivo Microsystems Technologies, LLC received a $2.04 million Phase 2 Small Business Innovation Research (SBIR) Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). Awarded on September 19, 2025, with completion targeted for August 31, 2027, this grant supports a multi-center clinical study to advance a novel near-infrared (NIR)...
Federal Grant Award Summary: Raylife Inc. – Non-Invasive Glucose Monitoring Technology Raylife Inc. received a $304,898 Small Business Innovation Research (SBIR) Phase I award from the National Science Foundation's Directorate for Technology, Innovation, and Partnerships (CFDA 47.084) for the period July 1, 2026 through June 30, 2027. The project focuses on developing a needle-free, wearable optoelectronic device capable of non-invasive, continuous blood glucose monitoring. The technology employs broadband volumetric spatiotemporal spectroscopy across the visible, near-infrared, and shortwave infrared spectrum (500–2500 nanometers) combined with physics-informed machine learning models to achieve clinical-grade accuracy while eliminating the need for subcutaneous sensors that require frequent replacement. The primary deliverable is validation of a high-risk, high-reward innovation platform designed to overcome decades of unsuccessful attempts at non-invasive glucose monitoring. By addressing the technical challenge of separating glucose-specific optical signals from confounding variables such as tissue scattering, temperature fluctuations, and motion artifacts, the device aims to improve user comfort, reduce costs, and increase accessibility for the estimated millions of people with diabetes and prediabetes. Beyond medical applications, the technology has commercial potential in the consumer wellness market. This Phase I funding supports NSF's national objective of advancing healthcare innovation, reducing chronic disease burden, and establishing U.S. leadership in next-generation biosensing technology.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $304.9k | 6/17/26 |